Fosnetupitant and palonosetron injection and Ivacaftor Granules
Determining the interaction of Fosnetupitant and palonosetron injection and Ivacaftor Granules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Fosnetupitant may significantly increase the blood levels of ivacaftor from certain formulations. This may increase the risk and/or severity of serious side effects such as liver damage. A dosage adjustment may be required. Talk to your doctor if you have any questions or concerns, or if you do not know whether your dosage has already been adjusted. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. In study subjects, ivacaftor peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.5- and 3.0-fold when it was administered concomitantly with fluconazole, a moderate CYP450 3A4 inhibitor. When lumacaftor/ivacaftor was coadministered with ciprofloxacin, another moderate CYP450 3A4 inhibitor, lumacaftor Cmax and AUC decreased by 12% and 14%, respectively, while ivacaftor Cmax and AUC increased by 29% each. These changes are not considered clinically significant. Physiologically based pharmacokinetic (PBPK) simulations suggest that coadministration with moderate CYP450 3A4 inhibitors may increase elexacaftor AUC by 1.9- to 2.3-fold and tezacaftor AUC by approximately 2.1-fold.
MANAGEMENT: Please consult manufacturer's product labeling for complete dosing information.
For ivacaftor - The dosage for patients 6 years or older should be reduced to 150 mg once daily when used with moderate CYP450 3A4 inhibitors (2 to
- "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
Generic Name: fosnetupitant / palonosetron
Brand name: Akynzeo for injection
Synonyms: Fosnetupitant and palonosetron (injection), Fosnetupitant and Palonosetron
Generic Name: ivacaftor
Brand name: Kalydeco
Synonyms: Ivacaftor
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fosnetupitant and palonosetron injection-Ivacaftor Tablets
- Fosnetupitant and palonosetron injection-Ivermectin
- Fosnetupitant and palonosetron injection-Ivermectin (Systemic)
- Fosnetupitant and palonosetron injection-Ivermectin Cream
- Fosnetupitant and palonosetron injection-Ivermectin Lotion
- Fosnetupitant and palonosetron injection-Ivermectin Tablets
- Ivacaftor Granules-Fosnetupitant/palonosetron Intravenous
- Ivacaftor Granules-Fosphenytoin
- Ivacaftor Granules-Fosphenytoin Injection
- Ivacaftor Granules-Fosphenytoin Sodium
- Ivacaftor Granules-Fospropofol Intravenous
- Ivacaftor Granules-Fosrenol